Position:Home >> News >> News information
Lansen Pharmaceutical Holdings Limited, the State Torch Program Certificate
PubTime:2016-06-08  Views:886  Text Display:L M S Print

(February 27, 2012, HONG KONG) - China's leading rheumatologists slow-acting prescription medicine expert Lansen Pharmaceutical Holdings Limited ( "Lansen Pharmaceutical" or the "Group") (stock code: 503), today announced its wholly owned subsidiary - Ningbo Lihua pharmaceutical Co., Ltd. ( "Ningbo Lihua") responsible for the production, treatment of rheumatoid arthritis drug TGP glycosides capsules (trade name "Pavlin") received by the State Science and technology section ( "Ministry") issued the "national torch program project certificate."

       National Torch Plan is approved by the State Council, the National Science and Technology Development of a mentoring program is responsible for organizing the implementation of the national high-tech industry is one of the most important programs aimed at promoting high-tech achievements in the domestic market has a good economic commercialization, industrialization of high-tech goods and high-tech industries internationalization. To its knowledge, it declared the project is very strict, declare competition is fierce.

       October 13, 2011, published on the website of the Ministry of Science issued on national science and technology projects related notice (the National Science count [2011] No. 420), the notice announced the 2011 National Spark Program, the Torch Plan 2011, the focus new product plans, soft science Research program project list of projects, the Ningbo Lihua "treatment of rheumatoid arthritis drug TGP glycosides capsule" was listed as 2011 national torch plan (item number: 2011GH021165), and in January 2012 officially Obtain the certificate.

       This project is a total glucosides of paeony capsules (Pavlin) a second state-level projects (in May 2010, "TGP glycosides capsule" national key new products, item number: 2010GRC22002). The Group believes that these national honor will further increase total glucosides of paeony capsules (Pavlin) visibility and market competitiveness, increase market, particularly doctors and patients, the effectiveness and quality of products recognized Pavlin, there sales of products to help Pavlin steady growth, market share continues to increase. Further, in the declaration, such as national or provincial and municipal science and technology project funding, the national high-tech enterprises, when the national or provincial engineering technology centers (application and acceptance), this certificate will be corroboration firm size and R & D capabilities, but also in the assessment the bonus items can further ensure the success rate of the company declared the project.
In recent years, Lansen Pharmaceutical attaches great importance to product development and research and development, focusing on identifying and developing the main areas in rheumatological therapy product and business development, but also greatly increase its investment in research and development. Achievement of this project further demonstrates the importance of the Group's research and development, and the progress made in the development and success. Lansen Pharmaceutical will continue its efforts, I believe the future there will be more and more R & D results.

Press inquiries:
Lansen Pharmaceutical Holdings Limited
Miss Pan Lirong
Phone: +852 28289243

About Lansen Pharmaceutical Holdings Limited

       Lansen Pharmaceutical is China's leading rheumatologists slow-acting prescription medicine specialist. Founded in 2002, the Group is principally engaged in the sales, production and development of prescription drugs in China Rheumatology specialist, with leading market position in China Rheumatology slow-acting drug market. Currently, in addition to 13 kinds of non-core drugs, Lansen Pharmaceutical has three rheumatism specialty prescription western core products, "TGP" and "properly express" the market share of the first and fourth. Group sales and marketing network covering the whole country four union territories, 25 provinces and cities, more than 1,000 hospitals. Production and management group headquartered in Ningbo City, Zhejiang Province, China, modernization of production facilities, covering about 64,000 square meters. In addition to having national GSP certification, the Group is also the production line has received GMP certification of the State Food and Drug Administration, and comply with stringent quality assurance and safety monitoring procedures.

About Torch Plan

       Torch Program was launched in August 1988, one of China's most important high-tech industry is recognized as planned. The plan approved by the State Council, the National Science and Technology is responsible for organizing the aim is to promote high-tech achievements in the domestic market has a good economic commercialization, industrialization of high-tech goods and high-tech industries internationalization. It declared the project is very strict, declare competition is fierce. The program includes the main raw materials, biotechnology, electronic information, including clean technology and other new technology projects.


 
 
Close】 【Top